title: No association between striatal dopamine transporter binding and body mass index: a multi-center European study in healthy volunteers.
abstract: BACKGROUND
  Dopamine is one among several neurotransmitters that regulate food intake and overeating. Thus, it has been linked to the pathophysiology of obesity and high body mass index (BMI). Striatal dopamine D(2) receptor availability is lower in obesity and there are indications that striatal dopamine transporter (DAT) availability is also decreased. In this study, we tested whether BMI and striatal DAT availability are associated.
  
  
  METHODS
  The study included 123 healthy individuals from a large European multi-center database. They had a BMI range of 18.2-41.1 kg/m(2) and were scanned using [(123)I]FP-CIT SPECT imaging. Scans were analyzed with both region-of-interest and voxel-based analysis to determine the binding potential for DAT availability in the caudate nucleus and putamen. A direct relation between BMI and DAT availability was assessed and groups with high and low BMI were compared for DAT availability.
  
  
  RESULTS
  No association between BMI and striatal DAT availability was found.
  
  
  CONCLUSIONS
  The lack of an association between BMI and striatal DAT availability suggests that the regulation of striatal synaptic dopamine levels by DAT plays no or a limited role in the pathophysiology of overweight and obesity.
authors.affiliation: Department of Nuclear Medicine, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands. elsmariekevandegiessen@gmail.com
authors.forename: Elsmarieke
authors.initials: E
authors.lastname: van de Giessen
authors.forename: Swen
authors.initials: S
authors.lastname: Hesse
authors.forename: Matthan W A
authors.initials: MW
authors.lastname: Caan
authors.forename: Franziska
authors.initials: F
authors.lastname: Zientek
authors.forename: John C
authors.initials: JC
authors.lastname: Dickson
authors.forename: Livia
authors.initials: L
authors.lastname: Tossici-Bolt
authors.forename: Terez
authors.initials: T
authors.lastname: Sera
authors.forename: Susanne
authors.initials: S
authors.lastname: Asenbaum
authors.forename: Renaud
authors.initials: R
authors.lastname: Guignard
authors.forename: Umit O
authors.initials: UO
authors.lastname: Akdemir
authors.forename: Gitte M
authors.initials: GM
authors.lastname: Knudsen
authors.forename: Flavio
authors.initials: F
authors.lastname: Nobili
authors.forename: Marco
authors.initials: M
authors.lastname: Pagani
authors.forename: Thierry
authors.initials: T
authors.lastname: Vander Borght
authors.forename: Koen
authors.initials: K
authors.lastname: Van Laere
authors.forename: Andrea
authors.initials: A
authors.lastname: Varrone
authors.forename: Klaus
authors.initials: K
authors.lastname: Tatsch
authors.forename: Jan
authors.initials: J
authors.lastname: Booij
authors.forename: Osama
authors.initials: O
authors.lastname: Sabri
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism*; D015992:Body Mass Index; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000378:metabolism*; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism*; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D014018:Tissue Distribution; D014326:Tropanes / Q000493:pharmacokinetics*
chemical_list: D050483:Dopamine Plasma Membrane Transport Proteins; D019275:Radiopharmaceuticals; D014326:Tropanes; C087552:2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane